Abstract:Cancer continues to present a substantial global health challenge, with its incidence and mortality rates persistently reflecting its significant impact. The emergence of precision oncology has provided a breakthrough in targeting oncogenic drivers previously deemed "undruggable" by conventional therapeutics and by limiting off-target cytotoxicity. Two groundbreaking technologies that have revolutionized the field of precision oncology are primarily CRISPR-Cas9 gene editing and more recently PROTAC (PROteolysis TArgeting Chimeras) targeted protein degradation technology. CRISPR-Cas9, in particular, has gained widespread recognition and acclaim due to its remarkable ability to modify DNA sequences precisely. Rather than editing the genetic code, PROTACs harness the ubiquitin proteasome degradation machinery to degrade proteins of interest selectively. Even though CRISPR-Cas9 and PROTAC technologies operate on different principles, they share a common goal of advancing precision oncology whereby both approaches have demonstrated remarkable potential in preclinical and promising data in clinical trials. CRISPR-Cas9 has demonstrated its clinical potential in this field due to its ability to modify genes directly and indirectly in a precise, efficient, reversible, adaptable, and tissue-specific manner, and its potential as a diagnostic tool. On the other hand, the ability to administer in low doses orally, broad targeting, tissue specificity, and controllability have reinforced the clinical potential of PROTAC. Thus, in the field of precision oncology, gene editing using CRISPR technology has revolutionized targeted interventions, while the emergence of PROTACs has further expanded the therapeutic landscape by enabling selective protein degradation. Rather than viewing them as mutually exclusive or competing methods in the field of precision oncology, their use is context-dependent (i.e., based on the molecular mechanisms of the disease) and they potentially could be used synergistically complementing the strengths of CRISPR and vice versa. Herein, we review the current status of CRISPR and PROTAC designs and their implications in the field of precision oncology in terms of clinical potential, clinical trial data, limitations, and compare their implications in precision clinical oncology.

Revolutionizing personalized cancer treatment: the synergy of next-generation sequencing and CRISPR/Cas9

CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer

Towards Personalized Cancer Care: A Report of CRISPR-Cas9 Applications in Targeted Therapies and Precision Medicine

Advances in Personalized Oncology

Harnessing the evolving CRISPR/Cas9 for precision oncology

Cancer treatment comes to age: from one-size-fits-all to next-generation sequencing (NGS) technologies

CRISPR/Cas9-based genome editing for multimodal synergistic cancer nanotherapy

CRISPR-Cas9 in cancer therapy: Revolutionizing oncology through targeted gene editing

CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions

Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction

CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment

Crispr/Cas9 Therapeutics: A Cure For Cancer And Other Genetic Diseases

Current progress in CRISPR-Cas systems for cancer

CRISPR-Cas9 technology: As an efficient genome modification tool in the cancer diagnosis and treatment

Innovative genetic scissor strategies and their applications in cancer treatment and prevention: CRISPR modules and challenges

CRISPR based therapeutics: a new paradigm in cancer precision medicine

Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics

Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed

The Potential Revolution of Cancer Treatment with CRISPR Technology

Recent advances in CRISPR-Cas systems for colorectal cancer research and therapeutics

Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?